جست‌وجوی استاد و پژوهشگر

Eugene Douglassمشاهده پروفایل

استادیار

• Cancer Research
• Drug Development
• Immunology
• +۷ مورد دیگر

Eugene Douglass is an Assistant Professor of Pharmaceutical and Biomedical Sciences at the University of Georgia (UGA) College of Pharmacy. He holds expertise in immunology, computational biology, and drug development, with a focus on cancer therapeutics and precision oncology. His research integrates spatial biology, organoid technologies, and systems pharmacology to address treatment-resistant malignancies and improve clinical translation. Dr. Douglass earned his B.S. in chemistry from Worcester Polytechnic Institute, followed by a Ph.D. in chemistry from Yale University. He completed postdoctoral training at Columbia University, where he contributed to drug-screening and RNA-sequencing infrastructure supporting clinical trials. His academic roles include teaching and advancing translational research initiatives in the College of Pharmacy. His research interests span cancer immunotherapy, organoid modeling of infectious diseases, and computational frameworks for drug discovery. Notable projects include developing time-based drug screening platforms and identifying novel therapeutic targets in glioblastoma and pancreatic cancer. He also explores mechanisms of multidrug resistance and leverages spatial biology to uncover therapy-resistant cancer stem cell populations. Dr. Douglass has pioneered tools to study drug distribution at tissue-blood barriers and contributed to the design of BCR-ABL1 kinase inhibitors for chronic myeloid leukemia. His work bridges 'big data' analysis with mechanistic insights, emphasizing clinically translatable discoveries.

• Urology
• Oncology
• Robotic Surgery
• +۳ مورد دیگر

Matthew Clements is an Assistant Professor at the University of Massachusetts Chan Medical School , affiliated with the Department of Surgery . His academic appointment spans both the UMass Chan Medical School and the T.H. Chan School of Medicine . Education: BS in Biochemistry from Virginia Polytechnic Institute and State University MS in Clinical Research from University of Virginia MD from University of Virginia School of Medicine Research Interests: Dr. Clements specializes in urology and oncology , with a focus on bladder cancer , prostate cancer , and robotic surgical procedures . His work emphasizes health-related quality of life assessments in surgical oncology and the use of validated clinical instruments for outcome measurement. Publication Trends: Recent articles (2023-2025) highlight advancements in non-muscle invasive bladder cancer treatment, robotic-assisted surgery outcomes, and prostate cancer survivorship. Key themes include microwave ablation for renal masses, low-intensity shockwave therapy for erectile dysfunction, and smoking history as a determinant of post-cystectomy quality of life. Collaborative Networks: Dr. Clements collaborates with colleagues in the Department of Surgery , including Barouch, Indes, O'Connor , and works alongside physical neighbors like Servais and Cheyuo . His research aligns with concepts such as urinary bladder neoplasms , laparoscopy , and cystectomy .

• Medical Oncology
• Urology
• Health Sciences
• +۳ مورد دیگر

Artur Lemiński is an Adjunct Professor in the Department of Biochemical Science at the Faculty of Health Sciences, Pomeranian Medical University in Szczecin. His research focuses on urological oncology, including prostate and bladder cancers, with emphasis on biomarkers, surgical outcomes, and prognostic factors. Key areas include lymphovascular invasion in prostate cancer, neoadjuvant chemotherapy efficacy, and the role of trace elements in cancer prognosis. He has published extensively on topics such as radical cystectomy outcomes, postoperative complications, and the application of artificial intelligence in uro-oncology. Research interests span tumor biology, surgical techniques, and clinical epidemiology. He leads studies on bladder preservation therapies, venous thromboembolism risk assessment in germ cell tumors, and the impact of the COVID-19 pandemic on urological emergency care. His work integrates clinical data with molecular and biochemical analyses, contributing to evidence-based practices in urological oncology. Notable contributions include systematic reviews on lymph node dissection in cystectomy patients and meta-analyses on preoperative predictors of lymphovascular invasion. His research often addresses gender disparities in cancer survival and the optimization of multidisciplinary approaches to genitourinary malignancies.

• Urology
• Oncology
• Bladder Cancer
• +۵ مورد دیگر

Dr. Siamak Daneshmand is a Professor of Urology and Medicine (Oncology) at the Keck School of Medicine of USC, serving as Director of Urologic Oncology and Urologic Oncology Fellowship Director. His expertise includes bladder, testicular, and kidney cancers, with a focus on perioperative outcomes, molecular markers, and surgical techniques like nerve-sparing RPLND. He leads clinical trials (e.g., SEMS, SWOG) and chairs the SUO-CTC Bladder Section. Research interests span bladder cancer pathways, biomarkers (e.g., miRNA, ctDNA), and functional outcomes post-cystectomy. He chairs AUA guidelines for bladder and testicular cancers and is an SWOG local bladder committee member. Key articles focus on testicular cancer survivorship, novel therapies (TAR-200), bladder preservation strategies, and genomic classifiers. Over 400 peer-reviewed publications highlight his contributions to urologic oncology. Scientific awards include 13 years as 'America’s Top Cancer Doctor' and Alpha Omega Alpha membership. He has led over a dozen clinical trials and serves on multiple steering committees.

Simon Crabbمشاهده پروفایل

استاد

• Bladder cancer
• Prostate cancer
• Predictive biomarkers
• +۴ مورد دیگر

Simon Crabb is a Professor of Experimental Cancer Therapeutics at the University of Southampton's School of Cancer Sciences and an Honorary Consultant in Medical Oncology at University Hospital Southampton NHS Foundation Trust. His research focuses on novel cancer treatments, precision medicine for bladder and prostate cancers, therapy resistance mechanisms, and epigenetic therapeutics. He leads multiple clinical trials, including early-phase studies for urological malignancies and serves as Associate Clinical Director of the Southampton Clinical Trials Unit and Clinical Programme Lead for the Southampton Experimental Cancer Medicine Centre. Education: MBBS (St George’s Hospital Medical School, 1996), PhD (Cancer Research UK Clinical Research Fellow, 2006) External Roles: Chair of Genomics England Clinical Interpretation Partnership for bladder cancer, member of NCRI Bladder/Renal and Prostate Groups, Cancer Research UK Expert Review Panel. Key research interests include biomarker-driven trials, combination therapies, and improving outcomes for muscle-invasive bladder and prostate cancers. He leads over 20 active clinical trials and has authored numerous high-impact publications in Cancers , European Journal of Cancer , and British Journal of Cancer . His work spans translational endpoints, drug development, and patient-centered symptom management. Current projects include the ELECTRA trial for intraoperative radiotherapy in rectal cancer, the GUSTO study for bladder cancer molecular subtyping, and the MANCAN2 trial evaluating CBT for prostate cancer-related symptoms.

• Urologic Oncology
• Biomarker Development
• Clinical Trial Design
• +۳ مورد دیگر

Fed Ghali, MD, is an Assistant Professor of Urology at the Yale School of Medicine, specializing in urologic oncology with expertise in bladder, ureter, kidney, and testicular cancers. He holds affiliations with Yale Cancer Center, Prostate & Urologic Cancers Program, and Urologic Oncology at Yale School of Medicine. Ghali completed his medical degree at Geisel School of Medicine, residency in Urology at UC San Diego, and a Society of Urologic Oncology fellowship at the University of Washington. His research focuses on clinical trial design, biomarker development for bladder cancer, and improving patient outcomes through personalized therapy. Notable interests include non-muscle invasive bladder cancer recurrence detection via urinary DNA analysis and optimizing treatment protocols for variant histology cancers. He collaborates with institutions nationally to advance therapeutic strategies and biomarker discovery. Ghali emphasizes patient-centered care, balancing high-volume clinical practice with compassionate individualized treatment. He actively participates in Yale's translational research initiatives and clinical trials to bring cutting-edge therapies to patients. His work highlights the integration of surgical innovation, molecular diagnostics, and clinical research in oncology.

Mostafa Fatemiمشاهده پروفایل

استاد

• Medical Imaging
• Ultrasonography
• Biomedical Engineering
• +۶ مورد دیگر

Mostafa Fatemi, Ph.D., is a Professor of Biomedical Engineering and Consultant in the Department of Physiology & Biomedical Engineering at Mayo Clinic. His research focuses on developing novel ultrasound-based technologies for disease diagnosis and monitoring, including vibro-acoustography, sub-hertz viscoelasticity assessment (SAVE), and microvascular imaging. He holds over 11 patents and has secured grants from NIH, NSF, and other institutions since 1998. Dr. Fatemi is a Fellow of multiple professional societies (IEEE, Acoustical Society of America, etc.) and received the IEEE Distinguished Lecturer Award (2016-2017). Education: PhD in Ultrasound Image Formation and Restoration, School of Electrical Engineering, Purdue University MS in Electrical Engineering, Iowa State University BS in Electrical Engineering, Shrif University Research Interests: Vibro-acoustography for detecting organ abnormalities (breast, thyroid, prostate) Noninvasive bladder function assessment Ultrasound-based microvasculature imaging for cancer and cardiovascular diseases Acoustically guided catheters for cardiac interventions Awards: IEEE Distinguished Lecturer Award (2016-2017) Fellowships: AIMBE, ASA, IEEE, AIUM Grants & Collaborations: NIH-funded projects on breast cancer, bladder function, and vascular disease Collaborations with Mayo Clinic clinicians and industrial partners for clinical translation

• Urology
• Reconstructive Surgery
• Bladder Cancer
• +۵ مورد دیگر

Prof. Dr. med. Margit Fisch is a faculty member at the University Medical Center Hamburg-Eppendorf, affiliated with the Department of Urology. Her research focuses on reconstructive urology, bladder cancer outcomes, and transgender healthcare.

Mattias Höglundمشاهده پروفایل

استاد

• Urothelial Cancer
• Molecular Classification
• Genomics
• +۳ مورد دیگر

Mattias Höglund is a Professor and Head of Division at the Lund University Cancer Centre (LUCC), focusing on urothelial cancer research. His work emphasizes molecular taxonomy, genomic profiling, and clinical applications of cancer subtypes. He leads the Uroscan-seq project and collaborates internationally on bladder cancer classification. Notable roles include Principal Investigator in multiple studies and academic leadership in LUCC. Research Interests: Molecular classification of urothelial carcinoma Genomics and epigenomics in cancer biology Bioinformatics-driven diagnostics Clinical translation of molecular subtypes Recent Articles: 2025: Investigated plasticity of bladder cancer subtypes across microenvironments 2024: Linked molecular subtypes to cisplatin treatment outcomes 2023: Defined the Lund taxonomy for bladder cancer classification Awards: No specific awards listed, but recognized for contributions to cancer genomics. Grants/Projects: Uroscan-seq: Translating molecular classification into clinical practice Multiple collaborative projects on bladder cancer subtypes and metastasis Labs/Teams: Active in LUCC and international networks, focusing on integrative genomic analysis and clinical-pathological correlations.

Michael J. Cimaمشاهده پروفایل

استاد

• Medical Devices
• Materials Science
• Drug Delivery Systems
• +۷ مورد دیگر

Michael J. Cima is the David H. Koch Professor of Engineering and Professor of Materials Science and Engineering at MIT, serving as Faculty Director of the Lemelson-MIT Program since 2009. He joined MIT's faculty in 1986 after earning a BS in Chemistry and PhD in Chemical Engineering from UC Berkeley. His research focuses on materials and engineered systems for improving human health, particularly in cancer treatment, metabolic disorders, and implantable medical devices. Key innovations include MIT's three-dimensional printing process, chemically derived epitaxial oxide films for superconductors, and implantable MEMS devices for drug delivery and diagnostics. Cima holds over 300 peer-reviewed publications and 90 patents. His research interests span medical device development, biomaterials, and translational technologies like non-invasive diagnostic tools for liver disease and bladder cancer therapies. Awards include membership in the National Academy of Engineering (2011) and National Academy of Inventors (2016), as well as the W. David Kingery Award (2019). The Cima Lab, under his leadership, pioneers advanced materials and medical technologies.

• Bladder Cancer
• Urothelial Biology
• Molecular Genetics
• +۳ مورد دیگر

Dr. Cathy Lee Mendelsohn is Professor of Urological Sciences in the Department of Urology and holds joint appointments in Pathology & Cell Biology and Genetics & Development at Columbia University. She serves as Principal Investigator of the George M. O'Brien Urology Research Center and is fluent in French, with expertise spanning urothelial biology and bladder cancer pathogenesis. Her academic background includes: BS in Microbiology from University of Massachusetts at Amherst PhD in Microbiology from Columbia University Graduate School of Arts and Sciences (1989) Dr. Mendelsohn's research investigates the molecular mechanisms governing urothelial differentiation and its dysregulation in disease. She specializes in nuclear receptor signaling (PPARγ, retinoids) and epigenetic regulation of urothelial homeostasis, with emphasis on how chronic injury triggers pathological shifts toward basal/squamous differentiation in bladder cancer. Her work bridges developmental biology and oncology to identify therapeutic targets. Analysis of her recent publications reveals a concentrated focus on PPARγ-mediated regulation of bladder cancer subtypes, particularly its role in suppressing basal/squamous differentiation through retinoid signaling and Kdm6a activation. A significant translational trend is evident in her preclinical development of rosiglitazone/trametinib combination therapy for muscle-invasive disease, now advancing to clinical trials. No scientific awards are documented in the provided text. Dr. Mendelsohn currently directs three major research initiatives: NIH U54 DK104309 (2014-2026): Investigating genetic/cellular mechanisms of urothelial homeostasis JPB Foundation grant (2021-2025): Exploring diabetes-urothelial differentiation-bladder cancer links Flare Therapeutics collaboration (2022-present): Testing PPARγ inverse agonists in bladder cancer models As PI of the George M. O'Brien Urology Research Center, she leads a multidisciplinary team utilizing advanced mouse models to dissect transcriptional and epigenetic pathways in urothelial regeneration and cancer progression, with active efforts to translate findings into clinical applications for high-grade bladder tumors.

• Statistics
• Public Health
• Cancer Research
• +۴ مورد دیگر

Oskar Hagberg is a statistician and researcher affiliated with Lund University's Faculty of Medicine and Department of Translational Medicine in Malmö. His work bridges statistics , public health , and cancer epidemiology , with a focus on bladder cancer and breast cancer detection, prognosis, and classification systems. Current Projects : Active in AI-integrated mammography screening (MASAI trial) and bladder cancer classification guidelines. Network : Collaborates with international cancer research teams and contributes to policy discussions. Hagberg’s research emphasizes statistical modeling for cancer outcomes, including delayed diagnosis mechanisms, AI’s impact on screening accuracy, and tumor grading standardization. His articles highlight interdisciplinary applications of data science in clinical oncology. Recent publications examine AI-driven mammography (2025), UTI-induced diagnostic delays in bladder cancer (2025), and histopathological grading systems (2024). These works align with UN Sustainable Development Goals for good health and well-being .

Marc C. Smaldoneمشاهده پروفایل

استاد

• Urologic Oncology
• Surgical Outcomes
• Health Services Research
• +۳ مورد دیگر

Marc C. Smaldone, MD, MSHP, FACS, is a Professor of Urology and Director of Surgical Quality at Fox Chase Cancer Center, part of Temple University Health System. He specializes in urologic oncology, focusing on robotic/laparoscopic surgery for cancers of the kidney, bladder, prostate, and adrenal glands. His research emphasizes quality of care, health disparities, and surgical outcomes in oncology. Education includes: Fellowship in Urologic Oncology at Fox Chase Cancer Center Residency at University of Pittsburgh School of Medicine MS in Health Policy Research from University of Pennsylvania MD from SUNY Stony Brook School of Medicine Research interests span comparative effectiveness, risk assessment, access disparities, and innovative surgical techniques for genitourinary cancers. His work consistently addresses quality improvement in cancer care delivery systems. Publications demonstrate strong focus on evidence-based surgical oncology, with recent articles exploring risk-stratified cancer management, racial disparities in treatment, and real-world outcomes data across urologic malignancies. Recurring themes include surgical quality metrics, minimally invasive techniques, and personalized treatment approaches. Awards and honors: Philadelphia Magazine Top Doctor (2023-2024) Main Line Today Top Doctor (2018-2019) Fellow of the American College of Surgeons Leads multidisciplinary teams at Fox Chase's Genitourinary Cancer Patient Care program, collaborating with medical and radiation oncology specialists. Current research includes NIH-funded trials on perioperative risk management and bladder cancer therapy optimization.

Inigo Martincorenaمشاهده پروفایل

پژوهشگر

• Somatic Mutation
• Cancer Genomics
• Ageing Research
• +۳ مورد دیگر

Inigo Martincorena is a Group Leader at the Wellcome Trust Sanger Institute, where he leads the Martincorena Group focused on somatic evolution research within the Cancer, Ageing and Somatic Mutation Programme. His career path includes positions as a CRUK Career Development Fellow, Research Fellow at Queens' College, University of Cambridge, and Postdoctoral Fellow at the Sanger Institute, demonstrating his deep integration within the academic research community. Dr. Martincorena's research centers on understanding somatic mutation and evolution in normal tissues and its implications for cancer development and ageing. His groundbreaking work has revealed that human tissues are mosaics of thousands of competing clones carrying cancer-driver mutations, fundamentally changing our understanding of early cancer development. His group has published seminal studies on somatic mutation landscapes in normal skin, esophagus, bladder, and other tissues, showing that these processes are widespread across human tissues. The Martincorena Group combines genome sequencing, laser capture microscopy, and computational data analysis to investigate somatic mutation dynamics, with current work focusing on characterizing somatic mutation in healthy tissues, exploring the role of somatic mutation in ageing and disease, studying somatic mutation in other species, and developing new experimental and computational methods. Among his notable scientific achievements, Dr. Martincorena holds the prestigious CRUK Career Development Fellowship and has developed dNdScv, an evolutionary method to study selection in cancer and somatic evolution that has become widely used in the field. His research has been published in top-tier journals including Nature, Science, and Cell, with multiple highly cited papers that have reshaped understanding of somatic evolution in normal tissues. Dr. Martincorena leads a research group within the Cancer, Ageing and Somatic Mutation Programme at the Sanger Institute, collaborating with numerous researchers and institutions worldwide. His group's work has significant implications for understanding cancer development, improving early detection methods, and potentially developing new approaches to prevent cancer. The Martincorena Group continues to push the boundaries of somatic mutation research with innovative methodologies and comprehensive analyses of normal tissue genomics.

• Health Economics
• Income-Related Inequality in Health
• Risk Behavior
• +۷ مورد دیگر

Ulf Gerdtham is a Professor at Lund University, jointly affiliated with the School of Economics and Management and the Medical Faculty. He is a Research Team Manager at the Department of Clinical Sciences, Malmö, and leads the Health Economics Unit. He also holds an Adjunct Professorship at Monash University Business School and serves as Research Director at the Swedish Institute of Health Economics. His research agenda centers on the interplay between economic factors and health-related behavior, with a focus on income-related health inequality, consequences of risky behavior and chronic diseases, and economic evaluations of health interventions. He has published extensively in journals like Journal of Health Economics and American Journal of Public Health . Recent publications highlight systematic reviews on loneliness interventions, cost-effectiveness analyses in oncology and mental health, and studies on child disability impacts. He leads major projects funded by the Swedish Council for Working Life and Social Research (Forte) and the Swedish Research Council, addressing health inequality, age-friendly policies, and dementia diagnostics. He has supervised 14 research works and contributes to the UN Sustainable Development Goals, particularly those related to health equity and well-being.